【摘要】 目的：分析给予EGFR突变肺腺癌患者埃克替尼靶向治疗的效果，评价其对于患者免疫功能与血清肿瘤标志物的影响。方法：选取2016年10月-2020年10月于山东省蒙阴县人民医院肿瘤科确诊并治疗的EGFR突变肺腺癌患者118例，应用随机综合平衡法将患者分为两组，各59例。对照组进行常规化疗，试验组进行埃克替尼靶向治疗，分析两组疗效、免疫功能、血清肿瘤标志物水平。结果：试验组总有效率高于对照组，差异有统计学意义(P<0.05)；治疗后试验组CD4+、CD8+以及CD4+/CD8+水平均高于对照组，差异有统计学意义(P<0.05)；治疗后试验组血清癌胚抗原、鳞状细胞癌相关抗原、糖类抗原125水平低于对照组，差异有统计学意义(P<0.05)。结论：给予EGFR突变肺腺癌患者埃克替尼靶向治疗的效果理想，可降低其血清肿瘤标志物水平，提升其免疫功能，对改善疾病预后具有重要意义，值得应用。更多还原

【Abstract】 Objective: To analyze the efficacy of icotinib targeted treatment in patients with EGFR-mutant lung adenocarcinoma,and to evaluate the effects on immune function and serum tumor markers of patients. Methods: A total of 118 patients with EGFRmutant lung adenocarcinoma who were diagnosed and treated in Department of Oncology, Mengyin County People’s Hospital from October 2016 to October 2020 were selected, and they were divided into two groups with 59 cases in each group by random comprehensive balance method. The control group received chemotherapy, while the experimental group received icotinib targeted therapy. The efficacy, immune function, and serum tumor marker levels of the two groups were analyzed. Results: The total effective rate in the experimental group was higher than that in the control group, and the difference was statistically significant(P<0.05). After treatment, the levels of CD4~+, CD8~+and CD4~+/CD8~+in the experimental group were higher than those in the control group, and the difference was statistically significant(P<0.05). After treatment, the serum levels of carcinoembryonic antigen,squamous cell carcinoma-related antigen and carbohydrate antigen 125 in the experimental group were lower than those in the control group, and the difference was statistically significant(P<0.05). Conclusion: The icotinib targeted therapy in patients with EGFR-mutant lung adenocarcinoma has an ideal effect, which can reduce the level of serum tumor markers and enhance immune function, and is of great significance in improving the prognosis of the disease and is worthy of application.更多还原